MDX 1303

Drug Profile

MDX 1303

Alternative Names: Anthrax anti-toxin monoclonal antibody - Altimmune/Medarex/Bristol-Myers-Squibb; Anti-anthrax monoclonal antibody - Altimmune/Medarex/Bristol-Myers-Squibb; MAb-1303; MDX-1303; Valortim

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medarex
  • Developer Altimmune; Bristol-Myers Squibb; Medarex
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Anthrax toxin inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anthrax
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Anthrax

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Anthrax(Prevention, In volunteers) in USA (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Anthrax(Prevention, In volunteers) in USA (IV, Infusion)
  • 04 May 2017 PharmAthene merged with Altimmune and the combined entity was renamed as Altimmune
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top